与KCNH1相关的性脑病变的分子基础以及开发向治疗的挑战
Alexandra K Sundman1,2, Shuyi Jin1,2, Lata Vadlamudi3,4
1Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia.
Brain : a journal of neurology
|September 23, 2025
概括
由KCNH1基因突变引起的KCNH1导致发育问题和发作. 向Kv10.1的阿洛斯特基调制剂为KCNH1相关脑病变提供了一个有前途的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 是一种神经系统疾病,有多种原因,包括遗传因素.
- KCNH1是由KCNH1基因的功能增益突变引起的,该基因编码Kv10.1通道.
- 这种情况是KCNH1相关脑病变的频谱的一部分,包括发育迟缓,智力障碍和婴儿发作.
研究的目的:
- 审查KCNH1的分子基础,临床特征和治疗策略.
- 讨论开发选择性抗发作药物的挑战.
- 为KCNH1提出治疗方法.
主要方法:
- 关于KCNH1的文献综述.
- 分析Kv10.1通道功能及其与Kv11.1 (hERG) 的关系.
- 对Kv10.1.1.的潜在治疗调节剂的评估.
主要成果:
- KCNH1突变会导致一系列的神经发育障碍,包括发作.
- Kv10.1通道与KCNH1有关.
- Kv11.1 (hERG) 通道由于其心脏作用而对药物选择性构成挑战.
结论:
- Kv10.1的基调节剂是KCNH1的有希望的治疗途径.
- 向Kv10.1的全调节剂可以提供更好的选择性来控制发作.
- 对于与KCNH1相关的脑病变,对KV10.1调节器的进一步研究是有必要的.
相关概念视频
Epilepsy and Seizures: Overview
1.2K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.2K
Antiepileptic Drugs: Potassium Channel Activators
635
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
635
Antiepileptic Drugs: Calcium Channel Blockers
1.2K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.2K
Antiepileptic Drugs: Sodium Channel Blockers
1.6K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.6K
Non-gated Ion Channels
8.0K
Ion channels are specialized proteins on the plasma membrane that allow charged ions to pass down their electrochemical gradient. Their main function is to maintain the membrane potential which is critical for cell viability. These channels are either gated or non-gated and can transport more than a thousand ions within milliseconds for the cellular event to occur.
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
8.0K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
831
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
831


